2023-08-01 07:04:04 ET
- Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $0.99 beats by $0.12 .
- Revenue of $954.61M (+4.7% Y/Y) beats by $44.2M .
- Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y)
- Jakafi (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023
- Opzelura (ruxolitinib) cream net product revenues of $80 million (+384% Y/Y) in Q2'23; continued uptake in atopic dermatitis ( AD ) and vitiligo
For further details see:
Incyte Non-GAAP EPS of $0.99 beats by $0.12, revenue of $954.61M beats by $44.2M